Evidence map›Paper›PMID 36982991›Full record

ArticleInternational journal of molecular sciences2023

Extracellular Vesicles of COVID-19 Patients Reflect Inflammation, Thrombogenicity, and Disease Severity.

Anat Aharon, Ayelet Dangot, Fadi Kinaani, Mor Zavaro, Lian Bannon, Tali Bar-Lev, Anat Keren-Politansky, Irit Avivi, Giris Jacob

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Human brain matters: Navigating the neuropathology of COVID-19.Brain pathology (Zurich, Switzerland) · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Anat AharonHematology Research Laboratory, Hematology Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 69978, Israel.
Ayelet DangotHematology Research Laboratory, Hematology Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 69978, Israel.
Fadi KinaaniDepartment of Medicine F, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
Mor ZavaroHematology Research Laboratory, Hematology Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 69978, Israel.
Lian BannonDepartment of Medicine F, Tel-Aviv Sourasky Medical Center, Tel Aviv 6423906, Israel.
Tali Bar-LevHematology Research Laboratory, Hematology Department, Tel-Aviv Sourasky Medical Center, Tel Aviv 69978, Israel.
Anat Keren-PolitanskyCoagulation Laboratory, Rambam Health Care Campus, Haifa 3109601, Israel.
Irit AviviThe Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
Giris JacobThe Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel.
Tel Aviv Sourasky Medical Center · ILTel Aviv University · ILRambam Health Care Campus · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe COVID-19 infections present with cytokine storms, hypercoagulation, and acute respiratory distress syndrome, with extracellular vesicles (EVs) being involved in coagulation and inflammation. This study aimed to determine whether coagulation profiles and EVs reflect COVID-19 disease severity. Thirty-six patients with symptomatic COVID-19 infection with mild/moderate/severe disease (12 in each group) were analyzed. Sixteen healthy individuals served as controls. Coagulation profiles and EV characteristics were tested by nanoparticle tracking analysis (NTA), flow cytometry, and Western blot. While coagulation factors VII, V, VIII, and vWF were comparable, significant differences were found in patients' D-Dimer/fibrinogen/free protein S levels compared to controls. Severe patients' EVs displayed higher percentages of small EVs (<150 nm) with increased expression of exosome marker CD63. Severe patients' EVs displayed high levels of platelet markers (CD41) and coagulation factors (tissue factor activity, endothelial protein C receptor). EVs of patients with moderate/severe disease expressed significantly higher levels of immune cell markers (CD4/CD8/CD14) and contained higher levels of IL-6. We demonstrated that EVs, but not the coagulation profile, may serve as biomarkers for COVID-19 severity. EVs demonstrated elevated levels of immune- and vascular-related markers in patients with moderate/severe disease, and may play a role in disease pathogenesis.

Indexed as

COVID-19ExosomesExtracellular VesiclesBiomarkersHumansInflammationPatient AcuityBiomarkersCOVID-19extracellular vesicles (EVs)inflammationthrombogenicity

Identifiers

PMID36982991
PMCPMC10054500
OpenAlexW4328121277

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.